New York State Common Retirement Fund Sells 8,742 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

New York State Common Retirement Fund lessened its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 237,126 shares of the company’s stock after selling 8,742 shares during the period. New York State Common Retirement Fund owned 0.88% of Castle Biosciences worth $5,117,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C bought a new stake in shares of Castle Biosciences during the 3rd quarter valued at about $15,988,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of Castle Biosciences by 112.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 547,403 shares of the company’s stock valued at $9,246,000 after purchasing an additional 289,252 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Castle Biosciences during the 3rd quarter valued at about $2,885,000. Principal Financial Group Inc. boosted its stake in shares of Castle Biosciences by 9.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,482,170 shares of the company’s stock valued at $25,034,000 after purchasing an additional 122,169 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of Castle Biosciences by 294.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 148,030 shares of the company’s stock valued at $2,500,000 after purchasing an additional 110,500 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $24.33 on Friday. Castle Biosciences, Inc. has a 1 year low of $9.26 and a 1 year high of $26.70. The stock has a market cap of $667.86 million, a P/E ratio of -21.16 and a beta of 0.93. The firm has a 50-day moving average of $20.86 and a 200 day moving average of $20.33.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.99%. The firm had revenue of $66.12 million for the quarter, compared to analysts’ expectations of $51.32 million. Research analysts expect that Castle Biosciences, Inc. will post -2.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 1,947 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $20.35, for a total transaction of $39,621.45. Following the transaction, the insider now directly owns 65,418 shares of the company’s stock, valued at $1,331,256.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the sale, the insider now directly owns 65,418 shares in the company, valued at approximately $1,331,256.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel Bradbury sold 2,400 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $20.45, for a total transaction of $49,080.00. Following the transaction, the director now owns 17,944 shares in the company, valued at approximately $366,954.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,483 shares of company stock valued at $1,059,531. Corporate insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CSTL shares. Scotiabank lifted their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st. Robert W. Baird lifted their target price on shares of Castle Biosciences from $33.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday. Finally, KeyCorp lifted their price target on shares of Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, March 1st.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.